论文部分内容阅读
目的比较聚乙二醇干扰素α-2a与恩替卡韦治疗慢性乙型肝炎患者的疗效与安全性。方法将60例慢性乙型肝炎患者随机分为干扰素组30例和恩替卡韦组30例;2组均常规护肝治疗。干扰素组给予聚乙二醇干扰素α-2a,恩替卡韦组另予恩替卡韦,观察治疗30周后2组患者的临床疗效。结果治疗后,2组丙氨酸氨基转肽酶(ALT)、天冬氨酸氨基转肽酶(AST)及总胆红素(TBIL)与治疗前比较,肝功能均有所改善(P<0.05);恩替卡韦组的ALT复常率(53.3%)、TBIL复常率(33.3%)和HBV-DNA转阴率(36.7%)明显高于干扰素组的ALT复常率(46.7%)、TBIL复常率(30.0%)和HBV-DNA转阴率(20.0%),差异有统计学意义(P<0.05);干扰素组(43.3%)的不良反应发生率高于恩替卡韦组(10.0%),差异有统计学意义(P<0.05)。结论恩替卡韦用于慢性乙型肝炎的抗病毒疗效明显优于聚乙二醇干扰素α-2a,且不良反应发生率小。
Objective To compare the efficacy and safety of pegylated interferon α-2a and entecavir in the treatment of chronic hepatitis B patients. Methods Sixty patients with chronic hepatitis B were randomly divided into interferon group (30 cases) and entecavir group (30 cases). Both groups were treated routinely with liver protection. Peginterferon alfa-2a was given in interferon group, entecavir was given in entecavir group, and the clinical efficacy was observed in two groups after 30 weeks of treatment. Results After treatment, the ALT, AST and TBIL in both groups were significantly improved (P < 0.05). The rates of ALT abnormality (53.3%), TBIL (33.3%) and HBV-DNA negative rate (36.7%) in entecavir group were significantly higher than those in interferon group (46.7% TBIL (30.0%) and HBV-DNA negative rate (20.0%), the difference was statistically significant (P <0.05); the incidence of adverse reactions in interferon group (43.3%) was higher than that in entecavir group ), The difference was statistically significant (P <0.05). Conclusion The anti-virus efficacy of entecavir for chronic hepatitis B is significantly better than that of peginterferon alfa-2a, and the incidence of adverse reactions is small.